Navigation Links
Clinverse, Inc. Announces Strategic Partnership With OmniComm Systems, Inc.
Date:9/4/2013

Raleigh, NC (PRWEB) September 04, 2013

Clinverse, Inc., a global technology and eclinical commerce network for clinical trials, announced today it has formed a strategic partnership with OmniComm Systems, Inc., a leading provider of EDC solutions.

Clinverse’s ClinPay solution automates sponsor payments to clinical vendors, investigators, and other parties throughout the entire financial life-cycle of a clinical trial. OmniComm’s TrialMaster EDC suite automates data collection and data validation and offers the unique capabilities of centralized monitoring with auto-redaction and automated SDTM export utility, allowing for efficient and cost-effective trial management.

Together with ClinPay, the combined solution automatically evaluates study data within the EDC system against contract criteria and directly generates financial transactions and all related accounting information. This combination optimizes cost savings by streamlining an inherently error-prone manual process and substantially reduces labor costs associated with the payment and accounting process for clinical vendors and investigative sites.

“We are pleased to be in a strategic partnership with such an innovative and forward-thinking EDC provider as OmniComm,” said Steve Ayala, Clinverse President and head of strategic partnerships. “OmniComm’s global footprint expands Clinverse’s reach to a broader international audience of pharmaceutical and biotech companies, CROs, research, and medical device organizations that can greatly benefit from automated payment capabilities in conjunction with their EDC services.”

Clinverse’s open application programming interface (API) allows for seamless integration with existing systems, such as OmniComm’s TrialMaster suite, as well as other external eclinical data sources, such as CTMS, IxRS, ERP systems, and data warehouses. When integrated with OmniComm’s TrialMaster EDC, sponsors and/or CROs are assured that accurate and direct financial transaction data feeds are automatically routed through the appropriate channels resulting in consistent and timely payments, whether by procedure, visit or any other contracted term.

“Most of the clinical sites we work with are required to use multiple EDC systems for various studies. Two of their biggest frustrations are the lack of intuitiveness of most EDC systems and the need for accurate and timely study payments,” stated Kuno van der Post, SVP of Business Development, OmniComm Systems, Inc. “Partnering with Clinverse and offering our TrialMaster EDC alongside their ClinPay solution allows us to make an exceptionally positive impact at the sites by addressing both of these key concerns.”

About OmniComm Systems, Inc

OmniComm Systems, Inc. (http://www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

About Clinverse, Inc.

Clinverse, Inc. is a global technology and financial services company that delivers highly secure, cloud-based financial management and payment solutions for the clinical trials industry. Founded in 2008 and headquartered in Raleigh, NC, the company delivers clinical financial solutions through the only truly collaborative and transparent financial management and payment platform. Used by leading BioPharma companies, Clinverse has developed ClinPay®, a fully-configurable, game-changing SaaS-based platform which manages tens of millions of dollars in financial transactions for thousands of global sites while supporting payments in 140 different currencies. For more information, please visit http://www.clinverse.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11075428.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Denis Connaghan Joins Clinverse, Inc. as Chief Executive Officer
2. Bud Owen and Tony Click Join Clinverse, Inc. as Chief Financial Officer and Chief Technology Officer
3. Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013
4. Clinverse, Inc. Introduces ClinSpend to Meet Challenges of Sunshine Act Reporting Requirements
5. Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC
6. iLab Solutions Announces the Results of the 2013 Core Facility Benchmarking Study
7. JULABO USA Inc. Announces Update on Product Finder Tool
8. ATCC Announces Creation of Biomaterial Contributor Network
9. Suria Plastic Surgery Announces an Open House at Their Plantation, Florida Office
10. SCD-iBIO Announces Second International Forum on Commercializing Global Green
11. Epic Sciences Announces Appointment of Dr. Murali Prahalad as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):